Novo Nordisk

Oral GLP-1 receptor drugs emerge as the next frontier in obesity treatment, with key players racing for first approval amidst…

The move taps into surging demand for appetite-suppressing GLP-1 agonists, set against ongoing shortages of newer weight-loss…

The market for oral GLP-1RAs is expanding, and Rybelsus’ latest results showed its benefits in reducing the risk in cardiovascular…

2024 top biotech and pharma employers survey by Science magazine identifies leading companies in the industry

Evotec to receive funding and potential milestone payments as Novo Nordisk explores stem cell-based therapies in diabetes and…

16 new weight-loss drugs anticipated by 2029, potentially expanding the market to $200 billion by 2031, as competition heats up

The showcase hosted by The Work from LIONS, in collaboration with Medulla Communications, analysed the most impactful campaigns…

As obesity rates rise and trust in GLP-1R products grows, sales for drugs targeting this receptor are forecast to increase…

High inflation and interest rates along with an uncertain business environment have disincentivised investment. The focus shifts…

Biopharma sector sees market capitalisation rise to $4 trillion, driven by strong performances from Lilly, Novo Nordisk, and…